Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $1.41M | $8.35M | $15.0M | $78.0M | $383M | $38.0M | $37.0M | $51.0M | $33.0M |
| Revenue growth | — | — | 491.2% | 79.6% | 420.0% | 391.0% | -90.1% | -2.6% | 37.8% | -35.3% |
| Operating income | -$18.2M | -$53.4M | -$54.9M | -$88.7M | -$124M | $54.0M | -$280M | -$340M | -$330M | -$386M |
| Operating margin | — | -3782.1% | -656.8% | -591.4% | -159.0% | 14.1% | -736.8% | -918.9% | -647.1% | -1169.7% |
| Net income | -$18.0M | -$53.1M | -$49.6M | -$84.7M | -$123M | $53.0M | -$267M | -$307M | -$283M | -$353M |
| Net margin | — | -3756.7% | -593.7% | -564.7% | -157.7% | 13.8% | -702.6% | -829.7% | -554.9% | -1069.7% |
| EPS (diluted) | -$20.80 | -$29.03 | -$1.43 | -$1.93 | -$2.24 | $0.71 | -$3.71 | -$4.15 | -$3.14 | -$3.29 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.9M | -$25.1M | -$43.0M | -$73.5M | $111M | -$256M | $438M | -$306M | -$170M | -$482M |
| Capital expenditures | $4.10M | $5.51M | $3.74M | $1.93M | $3.00M | $26.0M | $6.00M | $24.0M | $6.00M | $2.00M |
| Free cash flow | -$17.0M | -$30.6M | -$46.7M | -$75.4M | $108M | -$282M | $432M | -$330M | -$176M | -$484M |
| Share buybacks | — | — | $0.00 | $94.0K | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $65.2M | $98.4M | $71.1M | $57.9M | $173M | $148M | $206M | $127M | $150M | $222M |
| Total assets | — | $190M | $275M | $203M | $772M | $1.59B | $1.34B | $1.09B | $1.15B | $1.14B |
| Total liabilities | — | $36.6M | $40.0M | $39.3M | $270M | $750M | — | — | — | — |
| Long-term debt | — | — | — | — | — | — | — | $0.00 | $48.0M | $99.0M |
| Shareholders' equity | -$20.0M | -$72.3M | $235M | $164M | $502M | $842M | $657M | $462M | $485M | $631M |
| Retained earnings | — | -$73.2M | -$123M | -$205M | -$328M | -$275M | -$542M | -$849M | -$1.13B | -$1.49B |
| Shares (wtd avg diluted) | 3.37M | 3.89M | 36.4M | 43.8M | 54.8M | 74.0M | 72.0M | 74.0M | 90.1M | 107M |
Every figure is extracted from Arcus Biosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.